SXTP News & Events

60 Degrees Pharmaceuticals announced that the company has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify castanospermine from the seeds of Castanospermum australe for non-prescription uses. Castanospermine is the principal component of Australian Chestnut Extract. The FDA has issued a Non-Notification Letter to 60 Degrees Pharma providing feedback on the company's recent filing of a New Dietary Ingredient Notification for Australian Chestnut Extract. 60 Degrees Pharma and the Agency will meet on July 1 to discuss the feedback, including clarification regarding the minimum required "other safety information" to establish the safety of the proposed use of Australian Chestnut Extract in a dietary supplement. Subsequently, the company will submit a revised NDIN.

60 Degrees Pharmaceuticals announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. This patient enrollment puts the Company approximately one month ahead of schedule in recruiting trial participants for the 2026 tick season, suggesting that minimum enrollment in the study could be achieved as soon as early July. Approximately 50 days following enrollment completion, the Company intends to announce the planned date of the interim analyses of study data.